EPISODE · Oct 27, 2025 · 15 MIN
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
from OncLive® On Air · host OncLive® On Air
In today’s episode, we had the pleasure of speaking with Armeen Mahvash, MD, about the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. Dr Mahvash is a professor in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas MD Anderson Cancer Center in Houston, as well as an assistant professor in the Department of Diagnostic and Interventional Imaging at The University of Texas Medical School at Houston.In our exclusive interview, Dr Mahvash discussed the significance of this approval, key clinical findings that led to the approval, and how multidisciplinary collaboration is crucial for implementing radioembolization in practice.
Embed this episode
What this episode covers
Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
NOW PLAYING
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.